Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. 20 May 2020. Joerg Hausleiter.

Executive Summary

Edwards Lifesciences received the CE mark for its PASCAL transcatheter system for treating triscuspid valve regurgitation, competing against Abbott’s newly CE-marked TriClip. See what Joerg Hausleiter, a professor at the Medizinische Klinik der Ludwig-Maximilians-Universitaet in Germany said about it here.

Although the prevalence of tricuspid valve disease and the associated mortality are high, there are limited effective treatment options for these very symptomatic patients, who often cannot have surgery due to the prohibitive risk.” – Joerg Hausleiter, professor, Medizinische Klinik der Ludwig-Maximilians-Universitaet

Find out more: Edwards Receives CE Mark For PASCAL Transcatheter Tricuspid Valve Repair System

Click here for a free trial of Medtech Insight

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts